After a string of product recalls and products liability lawsuits, the chief executive officer of Johnson & Johnson is reportedly stepping down from his position later this spring. Although the New Jersey company's revenue has doubled in the past decade, the many product recalls in recent years have reportedly cost Johnson & Johnson more than $1 billion, as well as the serious hits to its public image and consumers' trust.
Earlier this week, we began an in-depth look into the convoluted process by which Johnson & Johnson and its unit DePuy Orthopaedics sought FDA approval for its articular surface replacement devices, or ASRs. Initially, the FDA rejected the medical product, stating that additional clinical study was necessary to determine whether the product was safe.
New documents have revealed that DePuy Orthopaedics, a unit of New Jersey-based Johnson & Johnson, continued to sell faulty hip replacement joints internationally after they were rejected for sale by the U.S. Food and Drug Administration. At the same time, DePuy sold a similar defective product in the U.S. after was approved through the FDA's 501(k) loophole, which we detailed extensively in a previous product liability blog post.
When a 50-year-old woman discovered a marble-sized lump in her breast, she went to her doctor for a mammogram, hoping and praying that she did not have breast cancer. She thought her prayers were granted when her doctor concluded that there was "no evidence of malignancy" in the lump. He did not order any additional tests, and she trusted his diagnosis.
On July 1, seven friends and members of New Jersey's 'Last Chance Motorcycle Club' were enjoying a motorcycle ride together when tragedy struck. A pickup truck driven by a highly intoxicated man collided directly into the group of motorcyclists. Ultimately, the motorcycle accident resulted in two fatalities and caused four of the bikers to be seriously injured. Only one escaped unharmed.
Recently, the faulty metal-on-metal hip replacement joints manufactured by DePuy Orthopaedics, a unit of New Jersey-based Johnson & Johnson, have become the subject of scrutiny and debate after causing pain and injury to thousands of patients. According to a few new studies, those defective products may continue to cause harm long after they are removed from the body.
Last week, we wrote that the U.S. Food and Drug Administration had ordered additional research into the vaginal mesh products that have caused injury and even death to women throughout the country.
Earlier this week, we wrote about the recent influx of product liability lawsuits against New Jersey-based Johnson & Johnson regarding its vaginal mesh implant products, which have resulted in injury and death in hundreds of women throughout the country. The vaginal mesh suits are not the only litigation facing Johnson & Johnson at this time. The company is also defending itself against a growing class action products liability lawsuit after "mechanical failure" forced the recall of hundreds of artificial joints.
Two New Jersey-based companies are among the more than 30 businesses that must conduct studies and clinical trials on the safety and effectiveness of vaginal mesh implants, according to recent media reports. The U.S. Food and Drug Administration ordered the studies after receiving multiple reports of injuries and fatalities caused by the defective products, an agency spokesman said.